Skip to main content
    • Aa
    • Aa

Statins and myocardial remodelling: cell and molecular pathways

  • Karen E. Porter (a1) and Neil A. Turner (a1)

The advent of statins has revolutionised the treatment of patients with raised plasma cholesterol and increased cardiovascular risk. However, the beneficial effects of this class of drugs are far greater than would be expected from lowering of cholesterol alone, and they appear to offer cardiovascular protection at multiple levels, primarily as a result of their pleiotropic activity. Indeed, their favourable effects on the heart seem to be mediated in part through reduced prenylation and subsequent inhibition of small GTPases, particularly those of the Rho family. Such statin-mediated effects are manifested by reduced onset of heart failure and improvements in cardiac dysfunction and remodelling in heart failure patients. Experimental studies have shown that statins mediate their effects on the two major resident cell types of the heart–cardiomyocytes and cardiac fibroblasts–and thus facilitate improvement of adverse remodelling of ischaemic or non-ischaemic aetiology. This review examines evidence for the cellular effects of statins in the heart, and discusses the underlying molecular mechanisms at the level of the cardiomyocyte (hypertrophy, cell death and contractile function) and the cardiac fibroblast (differentiation, proliferation, migration and extracellular matrix synthesis). The prospects for future therapies and ongoing clinical trials are also summarised.

Corresponding author
*Corresponding author: Karen E. Porter, Division of Cardiovascular and Neuronal Remodelling, Worsley Building, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1D. Steinberg and A.M. Gotto Jr. (1999) Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. Journal of the American Medical Association 282, 2043-2050

2W.B. Kannel and D.L. McGee (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59, 8-13

3S.M. Grundy (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44, 720-732

4E.S. Istvan and J. Deisenhofer (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164

6J.J. Brugts (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal 338, b2376

7F.M. Sacks (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 335, 1001-1009

8The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 339, 1349-1357

9Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22

10J. Shepherd (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 333, 1301-1307

12P.M. Ridker (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 359, 2195-2207

13C.P. Cannon (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 350, 1495-1504

14J.C. LaRosa (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 352, 1425-1435

15T.R. Pedersen (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 294, 2437-2445

17J.A. de Lemos (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Journal of the American Medical Association 292, 1307-1316

19J. Davignon (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43

20J. Kjekshus (1997) The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure 3, 249-254

21K. Node (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108, 839-843

22A. Corsini (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics 84, 413-428

23J.K. Liao and U. Laufs (2005) Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 45, 89-118

24J. Pekkanen (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New England Journal of Medicine 322, 1700-1707

25P.Y. Liu (2009) Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119, 131-138

26M.A. Ostad (2009) Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 205, 227-232

27S.F. Su (2000) Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. American Journal of Cardiology 86, 514-518

28Y. Young-Xu (2003) Statins reduce the incidence of atrial fibrillation in patients with coronary artery disease. Journal of the American College of Cardiology 41 (Suppl. A), 301A

29S.G. Tsouli (2008) Should a statin be prescribed to every patient with heart failure? Heart Failure Reviews 13, 211-225

30J.M. Foody (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092

31T.B. Horwich , W.R. MacLellan and G.C. Fonarow (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. Journal of the American College of Cardiology 43, 642-648

32K. Ramasubbu (2008) Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. Journal of the American College of Cardiology 51, 415-426

34K.K. Khush (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 115, 576-583

35B.M. Scirica (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology 47, 2326-2331

36A. Kumar and C.P. Cannon (2008) The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Failure Clinics 4, 129-139

38O. Adam (2008) Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 118, 1285-1293

39J. Bauersachs (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104, 982-985

40H. Hasegawa (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. Journal of Molecular and Cellular Cardiology 35, 953-960

41S. Hayashidani (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873

42J.D. Luo (1999) Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology 26, 903-908

43R. Patel (2001) Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104, 317-324

44J.K. Liao (2002) Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation 110, 285-288

45L. Van Aelst and C. Souza-Schorey (1997) Rho GTPases and signaling networks. Genes and Development 11, 2295-2322

46F. Lezoualc'h (2008) Small GTP-binding proteins and their regulators in cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 44, 623-632

47O. Adam (2007) Role of Rac1 GTPase activation in atrial fibrillation. Journal of the American College of Cardiology 50, 359-367

48F. Custodis (2006) Association of RhoGDIα with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovascular Research 71, 342-351

49C. Maack (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108, 1567-1574

50A. Clerk and P.H. Sugden (2000) Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circulation Research 86, 1019-1023

52J.H. Brown , D.P. Del Re and M.A. Sussman (2006) The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circulation Research 98, 730-742

53A. Clerk (2001) Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. Molecular and Cellular Biology 21, 1173-1184

54M. Satoh (2006) Requirement of Rac1 in the development of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 103, 7432-7437

55H. Lu (2006) Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 114, 2271-2279

56V.P. Sah (1999) Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. Journal of Clinical Investigation 103, 1627-1634

57M. Higashi (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circulation Research 93, 767-775

58S. Satoh (2003) Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. Journal of Molecular and Cellular Cardiology 35, 59-70

59Y.X. Wang (2005) Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. European Journal of Pharmacology 512, 215-222

60T. Hattori (2004) Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109, 2234-2239

61W. Bao (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovascular Research 61, 548-558

63Y.M. Zhang (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB Journal 20, 916-925

64J.J. Hunter (1995) Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. Journal of Biological Chemistry 270, 23173-23178

65M. Zheng (2004) Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. American Journal of Physiology. Heart and Circulatory Physiology 286, H424-H433

66H. Kai (1998) Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circulation Research 83, 594-601

68K.E. Porter and N.A. Turner (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacology and Therapeutics 123, 255-278

69Q. Zhou and J.K. Liao (2010) Pleiotropic effects of statins. Basic research and clinical perspectives. Circulation Journal 74, 818-826

70R.D. Brown (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and Toxicology 45, 657-687

71P. Camelliti , T.K. Borg and P. Kohl (2005) Structural and functional characterisation of cardiac fibroblasts. Cardiovascular Research 65, 40-51

72K.T. Weber (2004) Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. Journal of Hypertension 22, 47-50

73I. Banerjee (2006) Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Annals of the New York Academy of Sciences 1080, 76-84

74P. Kohl (2004) Cardiac cellular heterogeneity and remodelling. Cardiovascular Research 64, 195-197

76D.L. Mann and M.R. Bristow (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849

77S. Mital and J.K. Liao (2004) Statins and the myocardium. Seminars in Vascular Medicine 4, 377-384

78S. Oi (1999) Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European Journal of Pharmacology 376, 139-148

79T. Nishikimi (2002) Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. European Journal of Pharmacology 453, 175-181

80U. Laufs (2002) Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovascular Research 53, 911-920

81K. Morikawa-Futamatsu (2006) HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sciences 79, 1380-1390

82P.L. Hordijk (2006) Regulation of NADPH oxidases: the role of Rac proteins. Circulation Research 98, 453-462

83M. Takemoto (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108, 1429-1437

84E.Y. Choi (2010) Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. European Journal of Pharmacology 627, 56-62

85K.C. Hwang (1996) Alpha 1-adrenergic receptor coupling with Gh in the failing human heart. Circulation 94, 718-726

86L. Wu (2006) Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Molecular and Cellular Biochemistry 284, 65-71

87J. Liu , Q. Shen and Y. Wu (2008) Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sciences 82, 991-996

88A. Planavila (2008) Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli. Biochimica et Biophysica Acta 1781, 26-35

89L. Hauck (2007) Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circulation Research 100, 50-60

90R.S. Whelan , V. Kaplinskiy and R.N. Kitsis (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annual Review of Physiology 72, 19-44

91K.A. Webster (2007) Programmed death as a therapeutic target to reduce myocardial infarction. Trends in Pharmacological Sciences 28, 492-499

92S. Verma (2004) Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. Journal of Surgical Research 119, 66-71

93M.W. Bergmann (2004) Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3β and transcription factor β-catenin. Journal of Molecular and Cellular Cardiology 37, 681-690

94G. Vilahur (2009) Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 206, 95-101

95S.P. Jones (2003) Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circulation Research 93, 697-699

96M. Ito (2004) Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110, 412-418

97S. Demyanets (2006) Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochemical Pharmacology 71, 1324-1330

98Y. Ogata (2002) Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. Journal of Cardiovascular Pharmacology 40, 907-915

99D.M. Rivera and B.D. Lowes (2005) Molecular remodeling in the failing human heart. Current Heart Failure Reports 2, 5-9

100X. Zheng and S.J. Hu (2005) Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacologica Sinica 26, 696-704

101M. Vaquero (2007) Effects of atorvastatin and simvastatin on atrial plateau currents. Journal of Molecular and Cellular Cardiology 42, 931-945

102Y.L. Lee , M.J. Blaha and S.R. Jones (2011) Statin therapy in the prevention and treatment of atrial fibrillation. Journal of Clinical Lipidology 5, 18-29

104A. Schmechel (2009) Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovascular Research 82, 100-106

105C.A. Souders , S.L. Bowers and T.A. Baudino (2009) Cardiac fibroblast: the renaissance cell. Circulation Research 105, 1164-1176

107G. Krenning , E.M. Zeisberg and R. Kalluri (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. Journal of Cellular Physiology 225, 631-637

108E.M. Zeisberg and R. Kalluri (2010) Origins of cardiac fibroblasts. Circulation Research 107, 1304-1312

109Y. Sun and K.T. Weber (2000) Infarct scar: a dynamic tissue. Cardiovascular Research 46, 250-256

111A. Shiroshita-Takeshita (2007) Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovascular Research 74, 75-84

112O.M. Moiseeva (2007) Effect of pravastatin on phenotypical transformation of fibroblasts and hypertrophy of cardiomyocytes in culture. Bulletin of Experimental Biology and Medicine 143, 54-57

113S.B. Haudek (2009) Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovascular Research 83, 511-518

115A. Akhmetshina (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis and Rheumatism 58, 2553-2564

116T. Meyer-Ter-Vehn (2008) Lovastatin inhibits TGF-β-induced myofibroblast transdifferentiation in human tenon fibroblasts. Investigative Ophthalmology and Visual Science 49, 3955-3960

117R. Rodrigues-Diez (2008) Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharmaceutical Research 25, 2447-2461

118Y.P. He (2008) Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin. Molecular and Cellular Biochemistry 317, 33-41

119J. Martin (2005) In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clinical and Experimental Pharmacology and Physiology 32, 697-701

120B. Tian (2003) Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. American Journal of Physiology. Heart and Circulatory Physiology 285, H1105-H1112

123J. Chen and J.L. Mehta (2006) Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. American Journal of Physiology. Heart and Circulatory Physiology 291, H1738-H1745

124K.E. Porter (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755

125K.E. Porter (2004) Tumor necrosis factor α induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovascular Research 64, 507-515

126N.A. Turner (2007) Simvastatin inhibits TNFα-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Journal of Molecular and Cellular Cardiology 43, 168-176

127B.I. Jugdutt (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108, 1395-1403

128O. Adam (2010) Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. Journal of the American College of Cardiology 55, 469-480

129K.G. Shyu (2010) Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-β1 in cultured cardiac fibroblasts. European Journal of Heart Failure 12, 219-226

130K.E. Porter and N.A. Turner (2002) Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 30, 120-126

131Z. Luan , A.J. Chase and A.C. Newby (2003) Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23, 769-775

132D. Tousoulis (2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. European Journal of Heart Failure 7, 1126-1132

133S. Sola (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology 47, 332-337

134J. Zhang (2005) Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovascular Drugs and Therapy 19, 13-21

135C.K. Wallace (2005) Simvastatin decreases myocardial tumor necrosis factor α content in heart transplant recipients. Journal of Heart and Lung Transplantation 24, 46-51

136N.A. Turner (2007) Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovascular Research 76, 81-90

137K.A. Eccles (2008) Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 200, 69-79

138C. Arnaud , V. Braunersreuther and F. Mach (2005) Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine 15, 202-206

139J. Beltowski , G. Wojcicka and A. Jamroz-Wisniewska (2009) Adverse effects of statins – mechanisms and consequences. Current Drug Safety 4, 209-228

140L. Marcoff and P.D. Thompson (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. Journal of the American College of Cardiology 49, 2231-2237

141B. Moosmann and C. Behl (2004) Selenoprotein synthesis and side-effects of statins. Lancet 363, 892-894

142M.F. Olson (2008) Applications for ROCK kinase inhibition. Current Opinion in Cell Biology 20, 242-248

143M. Dong (2010) Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discovery Today 15, 622-629

144J. Bain (2007) The selectivity of protein kinase inhibitors: a further update. Biochemical Journal 408, 297-315

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Altmetric attention score